Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these particular antibodies during natural HIV-1 infection, to their role preventing infection, boosting endogenous immune responses and clearing both free viral particles and persistently infected cells.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | info:eu-repo/semantics/article biblioteca |
| Language: | eng |
| Published: |
2017
|
| Subjects: | Virus de la Inmunodeficiencia Humana, Anticuerpos Monoclonales, Profilaxis de las Enfermedades, Human Immunodeficiency Virus, Monoclonal Antibodies, Disease Prophylaxis, |
| Online Access: | http://hdl.handle.net/20.500.12123/2005 https://doi.org/10.3389/fimmu.2016.00661 https://www.frontiersin.org/articles/10.3389/fimmu.2016.00661/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|